Ocugen signs term sheet with Roots Pharmaceutical to license OCU400 in Middle East, North Africa
OCGN•Ocugen licenses OCU400 in MENA
Ocugen signed a binding term sheet to license OCU400 for retinitis pigmentosa to Roots Pharmaceutical in the Middle East and North Africa.
Financial terms and supply agreement
- Upfront license fees and near-term development milestones of up to $4 million.
- Sales milestones of up to $255 million.
- Royalties set at 22% of net sales.
- Ocugen will manufacture and supply commercial OCU400 under a related supply agreement.
